InMed Pharmaceuticals (INM)

Executive Summary

InMed Pharmaceuticals is a clinical-stage biopharmaceutical company leveraging cannabinoid-based therapeutics and its proprietary IntegraSyn™ biosynthesis platform for rare cannabinoid manufacturing. The company's lead candidate, INM-755, is being evaluated for epidermolysis bullosa, a rare genetic skin disorder with no approved therapies, representing a significant unmet medical need. A second candidate, INM-088, targets glaucoma in preclinical development. InMed's dual focus on drug development and high-purity cannabinoid supply positions it uniquely in the biotech sector, though the company operates with a modest market valuation of ~$2.2 million as of May 2026. Key risks include clinical trial outcomes, regulatory hurdles, and competition from larger cannabinoid-focused firms. InMed's near-term value hinges on advancing INM-755 through clinical trials and expanding the IntegraSyn platform's commercial partnerships. The company's low valuation reflects early-stage status and limited revenue, but successful trial data or manufacturing collaborations could catalyze significant upside. Investors should monitor upcoming clinical readouts and partnership announcements as critical inflection points. While the cannabinoid space remains volatile, InMed's targeted approach to rare diseases and scalable manufacturing provides a differentiated investment thesis.

Upcoming Catalysts (preview)

• 2027INM-755 Phase 2 Clinical Data Readout40% success
• 2027INM-088 IND Filing or Phase 1 Initiation30% success
• TBDIntegraSyn Partnership or Licensing Deal50% success